Home › Funds › ARMISTICE CAPITAL, LLC › MLYS
ARMISTICE CAPITAL, LLC position in MLYS
Mineralys Therapeutics, Inc. · Health Care
ARMISTICE CAPITAL, LLC reported holding 1,040,000 shares of MLYS (Mineralys Therapeutics, Inc.) in its Q2 2026 13F filing — a position valued at US$28.1M, representing 0.37% of its reported portfolio and ranking #40 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed MLYS holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ARMISTICE CAPITAL, LLC's MLYS position evolved
ARMISTICE CAPITAL, LLC first disclosed a stake in MLYS in Q2 2025 at 178,000 shares (US$2.4M). The position peaked in Q1 2026 at 1,176,000 shares, worth US$31.9M. Across 5 filings, ARMISTICE CAPITAL, LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,040,000 shares valued at US$28.1M — a reduction of -136,000 shares quarter over quarter.. Notable position changes include a 185% increase in Q3 2025 (shares fell 4% over the following quarter), a 33% increase in Q4 2025 (shares fell 25% over the following quarter), a 74% increase in Q1 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 178.00K | $2.41M | New |
| Q3 2025 | 507.65K | $19.25M | Add |
| Q4 2025 | 676.03K | $24.53M | Add |
| Q1 2026 | 1.18M | $31.86M | Add |
| Q2 2026 | 1.04M | $28.06M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLYS and 13F data
MLYS (Mineralys Therapeutics, Inc.) is a Health Care company. 53 other funds we track also report a position in MLYS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$207.6M), Catalys Pacific, LLC (US$196.0M), Samsara BioCapital, LLC (US$158.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLYS
- RA CAPITAL MANAGEMENT, L.P. 7.69M sh · $207.55M · Q2 2026
- Catalys Pacific, LLC 7.80M sh · $196.00M · Q3 2026
- Samsara BioCapital, LLC 5.87M sh · $158.40M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.96M sh · $106.79M · Q2 2026
- Laurion Capital Management LP 2.51M sh · $67.62M · Q2 2026
- ORBIMED ADVISORS LLC 2.11M sh · $56.94M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 1.56M sh · $42.20M · Q2 2026
- Andera Partners 1.59M sh · $40.00M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.47M sh · $39.66M · Q2 2026
- Ghisallo Capital Management LLC 1.12M sh · $30.35M · Q2 2026
- Logos Global Management LP 1.05M sh · $28.33M · Q2 2026
- Davern Capital Partners, LP 858.75K sh · $23.17M · Q2 2026
More on ARMISTICE CAPITAL, LLC
FAQ
How long has ARMISTICE CAPITAL, LLC held MLYS?
ARMISTICE CAPITAL, LLC has disclosed MLYS holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is ARMISTICE CAPITAL, LLC's current position in MLYS?
As of Q2 2026, ARMISTICE CAPITAL, LLC holds 1.04M shares of MLYS (Mineralys Therapeutics, Inc.), valued at $28.06M, representing 0.37% of its reported portfolio and ranking #40.
Has ARMISTICE CAPITAL, LLC been buying or selling MLYS?
In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC reduced its position in MLYS. The position peaked in Q1 2026 at 1.18M shares.
Which other funds hold MLYS?
Other major institutional holders of MLYS include RA CAPITAL MANAGEMENT, L.P., Catalys Pacific, LLC, Samsara BioCapital, LLC, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.